Dr. Xinsheng M. Liao

Jacob Mathew, MD is a fellowship trained, board-certified hematologist/oncologist who believes we are born with essential dignity and his goal is to preserve that dignity, at times using his medical knowledge and at other times just being there for his fellow man. Dr. Mathew believes that the practice of medicine should be evidence-based while simultaneously incorporating the art of medicine. To him, the art of medicine means he needs to be the advocate for his patients. He also hopes to empower his patients to play a pivotal role in their medical care and decision making by teaching them at least the basics of their disease. Dr. Mathew is rated as a Distinguished provider by MediFind in the treatment of Choriocarcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Pleuropulmonary Blastoma, Osteotomy, and Bone Marrow Aspiration.

Todd Yezefski is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Yezefski is rated as a Distinguished provider by MediFind in the treatment of Choriocarcinoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, Urothelial Cancer, and Hormone Replacement Therapy (HRT). Dr. Yezefski is currently accepting new patients.

John Paul Flores, MD, is a board-certified medical oncologist. He cares for patients with blood disorders and all forms of cancer.Dr. Flores takes the time to guide his patients on their wellness journey, listening to what they say, answering their questions and providing a path forward with hope. In this complex, fast-growing field where new treatments are approved for clinical use regularly, Dr. Flores relies on the expertise of a team of surgeons, pathologists, radiation oncologists and other colleagues to stay at the forefront of cancer treatment and to provide comprehensive, patient-centered care. Dr. Flores is rated as a Distinguished provider by MediFind in the treatment of Choriocarcinoma. His top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, Clear Cell Sarcoma, Prostatectomy, and Splenectomy.